Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty

This Phase II study evaluates the safety and efficacy of dasatinib and quercetin (D+Q) in improving physical function among individuals aged 50 or older with HIV who are frail or prefrail. The study enrolled 82 participants on stable antiretroviral therapy with viral suppression. Participants were randomized to receive either D+Q or placebo in six cycles over 12 weeks, followed by a 12-week monitoring period. The primary endpoints include the occurrence of Grade 2 or higher adverse events (AEs), premature treatment discontinuations, and changes in gait speed on a 4-meter walk. Although specific statistical outcomes are not yet reported, the study aims to assess whether D+Q can significantly enhance physical function in this population. Secondary endpoints and long-term effects are also under evaluation. Safety data will focus on the incidence of AEs and any treatment-related discontinuations. The results of this trial could inform future therapeutic strategies for managing frailty in older adults living with HIV.

This study focuses on older adults living with HIV, particularly those who are frail or at risk of becoming frail. Researchers are testing a combination of two drugs, dasatinib and quercetin, to see if they can help improve physical abilities, such as walking speed. Participants will take the treatment for 12 weeks, followed by a monitoring period to check for any lasting effects. The goal is to find out if this combination can make a real difference in their daily lives. If successful, it could lead to better ways to help older adults with HIV stay active and healthy. However, it’s important to note that the study is still ongoing, and results are not yet available. More research will be needed to confirm any benefits and understand the safety of these treatments.